Tier 2 — strong

Emerging roles of SIRT6 and its modulators in kidney diseases

Feihong Ren, Yudian Wang, Yufei Zhang, Liheng Liu, Qi Jin, Liping Yang, Yongli Zhan
Cell Death Discovery 2026 Online ahead of print

Bibliography

PubMed
PMID 42469212
DOI
10.1038/s41420-026-03264-y
Funding
Includes support from the National Natural Science Foundation of China (grant 82374277).

Study snapshot

DesignNarrative disease-mechanism and pharmacology review.
ModelPublished kidney-disease and SIRT6 literature.
SampleNot applicable.
InterventionNot applicable.
DurationNot applicable.
EndpointsKidney homeostasis; Acute kidney injury; Diabetic kidney disease; Hypertensive nephropathy; Renal fibrosis; Renal-cell carcinoma; SIRT6 modulators

What the study showed, in plain terms

This 2026 review synthesizes the increasingly complex kidney literature around SIRT6. It emphasizes that SIRT6 participates in renal homeostasis and multiple kidney diseases, but its effects depend on cell type and disease context.

Key findings

The review identifies SIRT6 as an important renal epigenetic regulator and summarizes emerging activators and inhibitors while stressing the translational challenge of cell-specific effects.

What this study can and cannot tell us

This is a review, not a clinical efficacy trial. Most SIRT6-targeted kidney interventions remain preclinical.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability